Professional Documents
Culture Documents
com/dividend-penny-stocks/great-stock-with-excellentmomentum-declares-special-1-00-dividend
Chart courtesy of www.StockCharts.com PetMeds stock has had a volatile year. After a bullish start, the companys share price dropped in early May on weaker fourth-quarter net income. After rebounding slightly, the companys share price fell further on weaker-than-expected first-quarter results. Since August however, the companys share price has been trending steadily higher, and recently broke through a resistance level near $11.50. While PetMeds second-quarter earnings and revenue results were essentially flat quarter-over-quarter, the company did repurchase 397,000 shares of common stock for $3.9 million, at an average share price of $9.74. Looking to the future, the company expects to focus its efforts on advertising efficiency and shifting sales to higher margin items, including generics, while continuing to expand its product offerings. We Told You So On Friday, October 9, financial analyst Mitchell Clark introduced you to ACADIA Pharmaceuticals Inc. (NASDAQ/ACAD) when it was trading at $2.63. Clark noted that Acadias share price had been climbing steadily higher since the beginning of September, after simply announcing it had completed its Phase III trial for its Parkinsons treatment he real good news for Acadia shareholders came on Tuesday, November 27, when the company announced successful results for the Phase III trial of its pimavanserin drug. The compound met the primary endpoint by demonstrating highly significant antipsychotic efficacy. The successful Phase III results helped lift Acadias share price to a new 52-week high of $6.54, for a shortterm gain of 148.6%.